Redeye comments on FluoGuide’s Q1 2025 report while the company’s phase II HNC interim readout draws ever closer (H2 2025e). We believe these data will pave the way for FG001 to enter pivotal HNC trials as soon as 2026e. Business development news should provide further catalysts in 2025e. We update our estimates and valuation.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/